1. CTCAE v5.0. 2. 100 mg patient with Gr3 pneumonitis confounded by recent treatment with CPI and concurrent hydropneumothorax in contralateral lung; 150 mg patient with Gr3 pneumonitis confounded by concurrent pneumocystis infection, had stopped zipalertinib 3 weeks prior to event; 100 mg patient with grade 1 pneumonitis treated with steroids with resolution and continued therapy; 65 mg patient with Gr 2 pneumonitis previously had pneumonitis on osimertinib. 16 Zipalertinib Phase 1/2a and pivotal study des ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) The unaudited consolidated financial statements for the quarter ended March 31, 2023, show a significant increase in net loss to $58.1 million, compared to $12.9 million in the prior-year period, primarily driven by higher R&D expenses [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2023, the company's total assets were $515.0 million, a decrease from $561.1 million at December 31, 2022 Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | March 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $122,128 | $156,152 | | Total current assets | $399,031 | $474,472 | | Total assets | $514,990 | $561,117 | | **Liabilities & Equity** | | | | Total current liabilities | $26,171 | $22,498 | | Total liabilities | $29,341 | $26,088 | | Total stockholders' equity | $485,649 | $535,029 | | Accumulated deficit | $(105,657) | $(47,695) | [Consolidated Statements of Operations and Comprehensive Income (Loss)](index=7&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20(Loss)) For the three months ended March 31, 2023, the company reported a net loss of $58.1 million, a substantial increase from the net loss of $12.9 million in the same period of 2022 Statement of Operations Highlights (in thousands, except per share data) | Metric | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Research and development | $52,096 | $24,536 | | General and administrative | $10,660 | $8,121 | | Loss from operations | $(62,756) | $(32,657) | | Interest income | $4,508 | $197 | | Net loss | $(58,141) | $(12,892) | | Net loss per share (basic and diluted) | $(1.42) | $(0.27) | [Consolidated Statements of Stockholders' Equity](index=8&type=section&id=Consolidated%20Statements%20of%20Stockholders%27%20Equity) Total stockholders' equity decreased from $535.0 million at the end of 2022 to $485.6 million as of March 31, 2023, mainly due to the quarterly net loss - The primary driver for the decrease in stockholders' equity was the net loss of **$58.1 million** for the quarter[22](index=22&type=chunk) - The company issued **647,500 shares of preferred stock** in exchange for **6,475,000 shares of common stock**[22](index=22&type=chunk) [Consolidated Statements of Cash Flows](index=9&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For Q1 2023, net cash used in operating activities was $51.0 million, a significant increase from Q1 2022, leading to a $34.0 million decrease in cash and cash equivalents Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | $(50,997) | $(21,908) | | Net cash provided by investing activities | $15,184 | $34,711 | | Net cash provided by financing activities | $1,789 | $3,541 | | Net decrease in cash and cash equivalents | $(34,024) | $16,344 | [Notes to the Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Consolidated%20Financial%20Statements) The notes detail key agreements, including a $25.0 million upfront R&D expense for a license agreement with Harbour BioMed, and confirm sufficient cash to fund operations for at least twelve months - The company is a clinical-stage biopharmaceutical company focused on modality-agnostic targeted oncology[28](index=28&type=chunk) - In February 2023, the company entered into a license and collaboration agreement with Harbour BioMed for CLN-418, paying a **$25.0 million upfront fee** which was immediately expensed as research and development[39](index=39&type=chunk)[63](index=63&type=chunk) - The company has a co-development agreement with Taiho for zipalertinib, where development costs and potential U.S. pre-tax profits are shared **50/50** For Q1 2023, Cullinan recorded a net R&D expense of **$3.7 million** related to this arrangement[64](index=64&type=chunk) - As of March 31, 2023, the company's cash, cash equivalents, and short-term investments of **$390.7 million** are expected to be sufficient to fund operations for at least twelve months from the issuance date of the financial statements[57](index=57&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's focus on advancing its six clinical-stage oncology product candidates, noting a significant increase in R&D expenses primarily due to a $25.0 million upfront license fee for CLN-418, while affirming sufficient capital for future operations - The company's pipeline includes six clinical-stage product candidates: Zipalertinib, CLN-049, CLN-619, CLN-418, CLN-978, and CLN-617[83](index=83&type=chunk) R&D and G&A Expense Comparison (in thousands) | Expense Category | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Research and development | $52,096 | $24,536 | | General and administrative | $10,660 | $8,121 | - The primary reason for the **$27.6 million increase** in R&D expenses was a **$25.0 million upfront fee** for in-licensing CLN-418[91](index=91&type=chunk) - Based on current plans, the company expects its cash, cash equivalents, and investments to be sufficient to fund operations for at least twelve months from the report's issuance date[98](index=98&type=chunk)[118](index=118&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not applicable as the company has elected to use the scaled disclosure requirements available to smaller reporting companies - The company is a smaller reporting company and has elected to omit the information required by this item[125](index=125&type=chunk) [Item 4. Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of March 31, 2023, with no material changes to internal controls over financial reporting during the quarter - Based on an evaluation as of March 31, 2023, the CEO and CFO concluded that the company's disclosure controls and procedures were effective at the reasonable assurance level[147](index=147&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, these controls[148](index=148&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=27&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is not currently a party to any legal proceedings that are expected to have a material adverse effect on its business - The company is not currently a party to any litigation or legal proceedings that management believes would have a material adverse effect on the business[150](index=150&type=chunk) [Item 1A. Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) This section refers investors to the detailed risk factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2022 - Investors are directed to carefully consider the risk factors discussed in Part I, 'Item 1A. Risk Factors' of the company's 2022 Annual Report on Form 10-K[151](index=151&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=28&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company provides an update on the use of proceeds from its Initial Public Offering (IPO) in January 2021, noting that none of the $264.5 million in net proceeds have been used as of March 31, 2023 - The company received net proceeds of **$264.5 million** from its IPO[152](index=152&type=chunk) - As of March 31, 2023, the company had not used any of the net proceeds from the IPO and has invested them in money market funds and marketable securities[152](index=152&type=chunk) [Item 3. Defaults Upon Senior Securities](index=28&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) Not applicable - This item is not applicable[152](index=152&type=chunk) [Item 4. Mine Safety Disclosures](index=28&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable - This item is not applicable[152](index=152&type=chunk) [Item 5. Other Information](index=28&type=section&id=Item%205.%20Other%20Information) Not applicable - This item is not applicable[152](index=152&type=chunk) [Item 6. Exhibits](index=29&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the quarterly report, including the License and Collaboration Agreement with Harbour BioMed and Sarbanes-Oxley Act certifications - Exhibit 10.2 is the License and Collaboration Agreement with Harbour BioMed US Inc., dated February 13, 2023[155](index=155&type=chunk) - Exhibits 31.1 and 31.2 are the required Sarbanes-Oxley Act Section 302 certifications from the CEO and CFO, respectively[133](index=133&type=chunk)[156](index=156&type=chunk) - Exhibit 32.1 contains the Sarbanes-Oxley Act Section 906 certifications[134](index=134&type=chunk)

PART I [Business](index=7&type=section&id=Item%201.%20Business) Cullinan Oncology is a clinical-stage biopharmaceutical company focused on modality-agnostic targeted oncology, with its lead candidate zipalertinib in a pivotal Phase 2b study for NSCLC. - The company's strategy is to identify high-impact cancer targets and then select the optimal therapeutic modality, sourcing innovation both internally and externally[57](index=57&type=chunk)[61](index=61&type=chunk) - In June 2022, Cullinan sold its equity interest in the Cullinan Pearl subsidiary to Taiho for an upfront payment of **$275.0 million**, granting Taiho worldwide rights to zipalertinib outside of Japan and Greater China, with co-development and co-commercialization in the U.S. sharing costs and profits equally[57](index=57&type=chunk)[450](index=450&type=chunk) - The company operates through a structure that includes partially-owned development subsidiaries such as Cullinan Florentine (CLN-049), Cullinan MICA (CLN-619), and Cullinan Amber (CLN-617), though it does not intend to create new subsidiaries in the future[91](index=91&type=chunk)[443](index=443&type=chunk) Cullinan Oncology Clinical & Preclinical Pipeline | Product Candidate | Target/Modality | Indication | Development Stage | | :--- | :--- | :--- | :--- | | **Zipalertinib** | EGFRex20ins Inhibitor | NSCLC | Pivotal Phase 2b | | **CLN-049** | FLT3/CD3 Bispecific Ab | AML / MDS | Phase 1 | | **CLN-619** | MICA/B Monoclonal Ab | Advanced Solid Tumors | Phase 1 | | **CLN-418** | B7H4/4-1BB Bispecific Ab | Advanced Solid Tumors | Phase 1 | | **CLN-978** | CD19/CD3 T-cell Engager | B-cell Non-Hodgkin Lymphoma | Phase 1 (IND Cleared) | | **CLN-617** | IL-2/IL-12 Fusion Protein | Solid Tumors | Preclinical (IND Filed) | [Risk Factors](index=59&type=section&id=Item%201A.%20Risk%20Factors) The company faces substantial risks related to its early-stage development efforts, heavy dependence on lead product candidates, and significant financial losses. - The company is substantially dependent on its lead product candidates, zipalertinib, CLN-049, CLN-619, and CLN-418, with failure to advance them materially harming the business[73](index=73&type=chunk)[332](index=332&type=chunk) - The company has incurred significant losses since inception and expects to continue incurring losses, requiring substantial additional funding that, if unavailable, may delay or eliminate development programs[306](index=306&type=chunk)[309](index=309&type=chunk) - Cullinan faces intense competition from major pharmaceutical and biotechnology companies with greater financial resources and expertise, who may develop or commercialize products more successfully or faster[2](index=2&type=chunk)[73](index=73&type=chunk) - The business relies on outsourcing manufacturing and clinical trial functions to third parties, whose failure to perform properly, meet deadlines, or comply with regulations could delay or prevent regulatory approval and commercialization[25](index=25&type=chunk)[371](index=371&type=chunk) - The company's ability to obtain and maintain patent protection for its product candidates is uncertain and critical to its success, facing a complex intellectual property landscape and potential infringement claims[392](index=392&type=chunk)[15](index=15&type=chunk) [Properties](index=112&type=section&id=Item%202.%20Properties) The company's corporate headquarters is located in Cambridge, Massachusetts, where it leases approximately 14,000 square feet of office space. - The company leases approximately **14,000 sq. ft.** for its headquarters in Cambridge, MA, with the lease expiring in July 2026, and an additional **8,000 sq. ft.** lease in the same city is substantially subleased to another tenant[34](index=34&type=chunk) [Legal Proceedings](index=112&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently a party to any litigation or legal proceedings that management believes would have a material adverse effect on its business. - As of the report date, the company is not involved in any legal proceedings expected to have a material adverse effect on its business[48](index=48&type=chunk) PART II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=113&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Cullinan Oncology's common stock trades on the Nasdaq Global Select Market under the symbol "CGEM", and the company has never paid cash dividends. - The company's common stock is traded on the Nasdaq Global Select Market under the ticker symbol "**CGEM**"[49](index=49&type=chunk) - The company has never paid cash dividends and does not intend to in the foreseeable future, retaining all available funds for business development[50](index=50&type=chunk) - The company's Initial Public Offering (IPO) was declared effective on January 7, 2021, raising aggregate net proceeds of approximately **$264.5 million**[38](index=38&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=114&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) For the year ended December 31, 2022, Cullinan Oncology reported net income of $109.2 million, primarily driven by a one-time gain from the sale of its Cullinan Pearl subsidiary. - The increase in R&D expenses was driven by higher costs for CLN-619 (**+$8.0M**), CLN-978 (**+$8.0M**), and CLN-617 (**+$9.9M**) due to advancing clinical and preclinical activities, partially offset by a decrease in zipalertinib expenses (**-$5.8M**)[457](index=457&type=chunk)[458](index=458&type=chunk) - As of December 31, 2022, the company had cash, cash equivalents, and short- and long-term investments totaling **$550.1 million**, expected to fund operations into 2026[486](index=486&type=chunk)[487](index=487&type=chunk) Results of Operations (2022 vs. 2021) | (in thousands) | Year Ended 2022 | Year Ended 2021 | | :--- | :--- | :--- | | License revenue | $0 | $18,943 | | Research and development | $91,948 | $57,751 | | General and administrative | $40,189 | $29,146 | | **Total operating expenses** | **$132,137** | **$86,897** | | Gain on sale of Cullinan Pearl | $276,785 | $0 | | **Income (loss) from operations** | **$144,648** | **($67,954)** | | Interest income | $6,611 | $477 | | Income tax expense | $42,121 | $0 | | **Net income (loss)** | **$109,195** | **($67,485)** | Cash Flow Summary (2022 vs. 2021) | (in thousands) | Year Ended 2022 | Year Ended 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($126,664) | ($43,433) | | Net cash provided by (used in) investing activities | $248,975 | ($333,775) | | Net cash provided by (used in) financing activities | ($25,933) | $268,784 | [Quantitative and Qualitative Disclosures About Market Risk](index=125&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a "smaller reporting company," Cullinan Oncology is not required to provide the information for this item. - The company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[531](index=531&type=chunk) [Financial Statements and Supplementary Data](index=125&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section contains the company's audited consolidated financial statements for the fiscal years ended December 31, 2022 and 2021, along with accompanying notes and the independent auditor's report. - The financial statements are accompanied by a report from the independent registered public accounting firm, KPMG LLP, which states that the statements present fairly the financial position and results of operations in conformity with U.S. GAAP[633](index=633&type=chunk) Consolidated Balance Sheet Highlights (As of Dec 31) | (in thousands) | 2022 | 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $156,152 | $59,774 | | Short-term investments | $311,140 | $230,692 | | Long-term investments | $80,882 | $140,397 | | **Total Assets** | **$561,117** | **$437,185** | | Total current liabilities | $22,498 | $11,746 | | **Total Liabilities** | **$26,088** | **$11,811** | | **Total Stockholders' Equity** | **$535,029** | **$425,374** | [Controls and Procedures](index=125&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures and internal control over financial reporting were effective as of December 31, 2022. - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2022[475](index=475&type=chunk) - Based on an assessment using the COSO framework, management concluded that the company's internal control over financial reporting was effective as of December 31, 2022[505](index=505&type=chunk) - No changes in internal control over financial reporting occurred during the fourth quarter of 2022 that materially affected, or are reasonably likely to materially affect, internal controls[506](index=506&type=chunk) PART III [Directors, Executive Officers and Corporate Governance](index=127&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) This section provides information on the company's executive officers and directors, including their ages, positions, and professional backgrounds. - The company's executive team includes Nadim Ahmed as President and CEO, Patrick Baeuerle, Ph.D., as Chief Scientific Officer, and Jeffrey Trigilio as Chief Financial Officer[537](index=537&type=chunk)[509](index=509&type=chunk)[510](index=510&type=chunk) - The Board of Directors has determined that all of its members are independent under Nasdaq rules, with the exception of CEO Nadim Ahmed[627](index=627&type=chunk) [Executive Compensation](index=130&type=section&id=Item%2011.%20Executive%20Compensation) The company's Named Executive Officers for 2022 were CEO Nadim Ahmed, CSO Patrick Baeuerle, and CFO Jeffrey Trigilio, with compensation packages consisting of base salary, bonuses, and equity awards. - Executive compensation is designed to attract and retain key employees through a mix of base salary, annual performance-based bonuses, and long-term equity incentives[516](index=516&type=chunk) 2022 Summary Compensation Table | Name | Position | Salary ($) | Bonus ($) | Stock/Option Awards ($) | All Other Comp. ($) | Total ($) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Nadim Ahmed | President & CEO | 618,000 | 370,800 | 2,762,750 | 148,977 | 3,900,527 | | Patrick Baeuerle, Ph.D. | Chief Scientific Officer | 463,500 | 266,234 | 1,196,250 | 34,000 | 1,959,984 | | Jeffrey Trigilio | Chief Financial Officer | 452,000 | 260,352 | 1,196,250 | 15,634 | 1,924,236 | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=137&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) As of February 15, 2023, the company's directors and executive officers as a group beneficially owned 8.34% of the outstanding common stock, with several institutional stockholders holding over 5%. - All executive officers and directors as a group beneficially owned **3,517,920 shares**, representing **8.34%** of the company's common stock as of February 15, 2023[586](index=586&type=chunk)[588](index=588&type=chunk) 5% or Greater Stockholders (as of Feb 15, 2023) | Name of Beneficial Owner | Percentage of Shares Beneficially Owned | | :--- | :--- | | UBS Oncology Impact Fund L.P. | 19.45% | | Entities affiliated with BVF, Inc. | 16.39% | | Entities affiliated with F2 Ventures | 9.62% | | CHI Advisors LLC | 8.44% | | The Vanguard Group | 7.15% | | BlackRock, Inc. | 6.37% | [Certain Relationships and Related Transactions, and Director Independence](index=140&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) This section details transactions involving the company and its related parties, including IPO participation and royalty agreements with affiliated foundations. - Certain executive officers and 5%+ stockholders, including entities affiliated with F2 Ventures and UBS Oncology Impact Fund, purchased shares in the company's January 2021 IPO[591](index=591&type=chunk)[564](index=564&type=chunk) - Several company subsidiaries are party to Royalty Transfer Agreements with the MPM Oncology Charitable Foundation and UBS Optimus Foundation, which are affiliated with a major stockholder (OIF) and a former director[566](index=566&type=chunk) - The company has a related person transaction policy requiring review and approval of transactions exceeding **$120,000** by the audit committee[596](index=596&type=chunk) [Principal Accountant Fees and Services](index=143&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) The company's independent registered public accounting firm is KPMG LLP, with total fees paid for 2022 amounting to $1,009,920 for audit and tax services. Accountant Fees (KPMG LLP) | Fee Category | 2022 | 2021 | | :--- | :--- | :--- | | Audit fees | $702,500 | $470,000 | | Tax fees | $307,420 | $104,210 | | **Total Fees** | **$1,009,920** | **$574,210** | PART IV [Exhibits and Financial Statement Schedules](index=144&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists the financial statements, financial statement schedules, and exhibits filed as part of the Annual Report on Form 10-K. - This section provides an index to the consolidated financial statements and a list of all exhibits filed with the 10-K report, including corporate governance documents, material contracts, and certifications[600](index=600&type=chunk)[755](index=755&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39856 CULLINAN ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 81-3879991 (State or other ju ...

| --- | --- | --- | --- | |---------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Mining for Tomorrow's Cures Cullinan Oncology Overview | | | | | Q3 2022 | | | | 2 Important notice and disclaimers This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our strategy, future financial condition, future operations, projected co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share CGEM The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39856 CULLINAN ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR Delaware 81-3879991 (State or other jurisd ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | Important notice and disclaimers This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39856 CULLINAN ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 81-3879991 (State or other jurisdictio ...

Mining for Tomorrow's Cures Cullinan Oncology Overview Q1 2022 Important notice and disclaimers This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-look ...